Research Analysts Set Expectations for NBIX FY2025 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of $5.83 per share for the year. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.93 per share.

Several other analysts also recently weighed in on NBIX. UBS Group upped their target price on Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Raymond James restated an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. BMO Capital Markets decreased their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $164.81.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $146.76 on Wednesday. Neurocrine Biosciences has a 1 year low of $110.95 and a 1 year high of $157.98. The stock has a 50 day simple moving average of $132.54 and a two-hundred day simple moving average of $131.19. The firm has a market cap of $14.86 billion, a P/E ratio of 39.35 and a beta of 0.33.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kyle Gano sold 65,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the transaction, the chief executive officer now directly owns 135,392 shares in the company, valued at $19,157,968. The trade was a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,694 shares of company stock valued at $9,676,730 over the last ninety days. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp boosted its position in Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after purchasing an additional 539,936 shares during the last quarter. Geode Capital Management LLC boosted its position in Neurocrine Biosciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company’s stock worth $213,773,000 after purchasing an additional 39,610 shares during the last quarter. AQR Capital Management LLC boosted its position in Neurocrine Biosciences by 23.0% in the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after purchasing an additional 228,444 shares during the last quarter. Braidwell LP boosted its position in Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock worth $105,734,000 after purchasing an additional 158,665 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Neurocrine Biosciences by 4.7% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 819,968 shares of the company’s stock worth $94,478,000 after purchasing an additional 37,098 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.